EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma

Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma. The EC previously granted orphan designations for pralatrexate for the treatment of patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and non-papillary transitional cell carcinoma (TCC) of the urinary bladder, a form of bladder cancer.

“The orphan medicinal product designation represents another important regulatory achievement for Allos and further strengthens our global development strategy for pralatrexate in patients with hematologic malignancies.”

Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics, said: "The orphan medicinal product designation represents another important regulatory achievement for Allos and further strengthens our global development strategy for pralatrexate in patients with hematologic malignancies."